Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615
This examiner grants 29% of resolved cases
Caralynne E. Helm is an examiner in Art Unit 1615 within Tech Center 1600. She has managed 799 resolved cases, providing a very large data set for analysis. Her allowance rate is 28.9 percent, which suggests a very rigorous examination environment. This 28.9 percent rate indicates that the majority of applications do not reach allowance, requiring a focused and effective prosecution strategy. The 799 resolved cases establish a clear baseline for her examination patterns in Art Unit 1615.
Despite the low baseline allowance rate, the data shows a significant interview lift of 49.6 percent. This is a critical insight for practitioners. The 49.6 percent lift indicates that interviews are exceptionally effective at improving the chances of success. In an environment where the overall allowance rate is only 28.9 percent, the boost provided by an interview can be the difference between a grant and an abandonment. Direct engagement should be a top priority for any application under her review.
The median days to allowance is 1494. This is a very long timeline, reflecting the difficulty of the prosecution process in Tech Center 1600. Applicants should plan for a pendency of approximately 1494 days. The combination of a 28.9 percent allowance rate and a 1494-day median pendency underscores the necessity of using the 49.6 percent interview lift to navigate the process. The 1494-day duration is a vital metric for managing client expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18591127 | Methods, Systems and Devices for Post-Fabrication Drug Loading | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 18105990 | SURFACE TREATMENT OF POLY(ARYL ETHER KETONE)S | Non-Final OA | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG e. V. |
| 17595159 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18029619 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPLANT ASSOCIATED COMPLICATIONS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18254312 | RAPIDLY RESORBABLE INTRAVASCULAR IMPLANT | Non-Final OA | BIOTRONIK AG |
| 18423951 | SURGICAL SYSTEM AND METHODS OF USE | Non-Final OA | Medtronic, Inc. |
| 18877255 | STABILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | Non-Final OA | L'OREAL |
| 18543756 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND AVOBENZONE | Final Rejection | L'OREAL |
| 17675334 | MEDICAL DEVICE AND METHOD FOR MANUFACTURING SAME | Final Rejection | TERUMO KABUSHIKI KAISHA |
| 17629639 | WATER BASED COMPOSITION | Final Rejection | Shiseido Company, Ltd. |
| 18700520 | COMPOSITIONS FOR DELIVERY OF CANNABINOIDS | Non-Final OA | PNEUMA RESPIRATORY, INC. |
| 17297836 | NON-ALUMINIUM ANTIPERSPIRANT COMPOSITIONS | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18009665 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEPSIS CONTAINING FUNCTIONALIZED TRANSITION METAL DICHALCOGENIDE | Non-Final OA | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS |
| 17392361 | REACTOR FOR PRODUCING PHARMACEUTICAL PARTICLES IN A PRECIPITATION PROCESS | Final Rejection | MannKind Corporation |
| 18755456 | METHODS AND FOODS INCLUDING SILVER COMPOUNDS TO PROTECT ANIMALS FROM PATHOGENIC BACTERIA AND DISEASE | Non-Final OA | SilverCeuticals Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy